Literature DB >> 9242339

Pancreatic resection combined with intraoperative radiation therapy for pancreatic cancer.

T J Farrell1, D J Barbot, F E Rosato.   

Abstract

OBJECTIVE: The objective of the study was to analyze a single center's experience in the treatment of pancreatic carcinoma with a combination of pancreatic resection and intraoperative radiation therapy (IORT). SUMMARY BACKGROUND DATA: Pancreatic cancer is the most lethal form of gastrointestinal malignancy. Historically, it carries a 20% 1-year survival and a 5-year survival of 3% to 5%. Since 1987, patients at Thomas Jefferson University Hospital have been offered IORT in an attempt to improve their survival.
METHODS: The authors reviewed all patients treated at Thomas Jefferson University Hospital with pancreatic adenocarcinoma from 1987 to 1994. From this population, 14 patients were identified who received IORT in conjunction with curative surgery. Duration of hospital stay, perioperative complications, duration of postoperative ileus, and survival were assessed by retrospective review.
RESULTS: Of the 14 patients, 6 were male and 8 were female. Patient median age was 61. Six patients had stage I disease, 2 had stage II, 6 had stage III. Two patients had total pancreatectomy, 2 had distal pancreatectomy, and the remaining had pancreaticoduodenectomy (Whipple resection). Median survival was 16 months with a 15.5% 5-year survival. Postoperative complications, duration of hospital stay, and duration of postoperative ileus were not adversely affected by the addition of IORT when compared to in-house control subjects.
CONCLUSIONS: Intraoperative radiation therapy is a useful adjunct to surgical resection as treatment of pancreatic cancer. The authors' data suggested it can prolong median survival and long-term survival without adding significant morbidity.

Entities:  

Mesh:

Year:  1997        PMID: 9242339      PMCID: PMC1190908          DOI: 10.1097/00000658-199707000-00009

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  9 in total

Review 1.  Pancreatic carcinoma.

Authors:  A L Warshaw; C Fernández-del Castillo
Journal:  N Engl J Med       Date:  1992-02-13       Impact factor: 91.245

2.  Long-term results of combined modality treatment with I-125 implantation for carcinoma of the pancreas.

Authors:  M Mohiuddin; F Rosato; D Barbot; A Schuricht; W Biermann; R Cantor
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

3.  Cancer of the pancreas. 50 years of surgery.

Authors:  B Gudjonsson
Journal:  Cancer       Date:  1987-11-01       Impact factor: 6.860

Review 4.  Perioperative blood transfusions and cancer recurrence.

Authors:  H S Wu; A G Little
Journal:  J Clin Oncol       Date:  1988-08       Impact factor: 44.544

5.  Electron beam intraoperative radiation therapy (EBIORT) for localized pancreatic carcinoma.

Authors:  M Kawamura; M Kataoka; T Fujii; H Itoh; M Ishine; K Hamamoto; S Yokoyama; S Takashima; M Satoh; K Inoue
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

6.  Patterns of failure after curative resection of pancreatic carcinoma.

Authors:  J F Griffin; S R Smalley; W Jewell; J C Paradelo; R D Reymond; R E Hassanein; R G Evans
Journal:  Cancer       Date:  1990-07-01       Impact factor: 6.860

Review 7.  Influence of multimodality therapy on the management of pancreas carcinoma.

Authors:  J M Jessup; M Posner; M Huberman
Journal:  Semin Surg Oncol       Date:  1993 Jan-Feb

8.  Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.

Authors:  C G Moertel; S Frytak; R G Hahn; M J O'Connell; R J Reitemeier; J Rubin; A J Schutt; L H Weiland; D S Childs; M A Holbrook; P T Lavin; E Livstone; H Spiro; A Knowlton; M Kalser; J Barkin; H Lessner; R Mann-Kaplan; K Ramming; H O Douglas; P Thomas; H Nave; J Bateman; J Lokich; J Brooks; J Chaffey; J M Corson; N Zamcheck; J W Novak
Journal:  Cancer       Date:  1981-10-15       Impact factor: 6.860

9.  Intraoperative radiation therapy following pancreaticoduodenectomy.

Authors:  D B Evans; P M Termuhlen; D R Byrd; F C Ames; T G Ochran; T A Rich
Journal:  Ann Surg       Date:  1993-07       Impact factor: 12.969

  9 in total
  9 in total

1.  Pancreatic resection combined with intraoperative radiation therapy for pancreatic cancer.

Authors:  C M Huiras
Journal:  Ann Surg       Date:  1999-12       Impact factor: 12.969

Review 2.  Adjuvant therapy in pancreatic cancer.

Authors:  P Ghaneh; J Slavin; R Sutton; M Hartley; J P Neoptolemos
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

3.  Different radiogenic effects on microcirculation in healthy pancreas and in pancreatic carcinoma of the rat.

Authors:  Eduard Ryschich; Jan Schmidt; Thorsten Loeffler; Michel Eble; Martha Maria Gebhard; Wolfgang Harms; Ernst Klar
Journal:  Ann Surg       Date:  2003-04       Impact factor: 12.969

Review 4.  [Therapy of pancreatic adenocarcinoma].

Authors:  M Böhmig; B Wiedenmann; S Rosewicz
Journal:  Med Klin (Munich)       Date:  1999-11-15

Review 5.  Phenotype and genotype of pancreatic cancer cell lines.

Authors:  Emily L Deer; Jessica González-Hernández; Jill D Coursen; Jill E Shea; Josephat Ngatia; Courtney L Scaife; Matthew A Firpo; Sean J Mulvihill
Journal:  Pancreas       Date:  2010-05       Impact factor: 3.327

6.  Treatment of pancreatic cancer: challenge of the facts.

Authors:  Hans G Beger; Bettina Rau; Frank Gansauge; Bertram Poch; Karl-Heinz Link
Journal:  World J Surg       Date:  2003-08-21       Impact factor: 3.352

Review 7.  Advances in the treatment of pancreatic cancer: limitations of surgery and evaluation of new therapeutic strategies.

Authors:  Yukihiro Yokoyama; Yuji Nimura; Masato Nagino
Journal:  Surg Today       Date:  2009-05-27       Impact factor: 2.549

8.  ESTRO IORT Task Force/ACROP recommendations for intraoperative radiation therapy in borderline-resected pancreatic cancer.

Authors:  Felipe A Calvo; Jose M Asencio; Falk Roeder; Robert Krempien; Philip Poortmans; Frank W Hensley; Marco Krengli
Journal:  Clin Transl Radiat Oncol       Date:  2020-05-15

9.  EphA2‑enriched exosomes promote cell migration and are a potential diagnostic serum marker in pancreatic cancer.

Authors:  Qian Wei; Lijuan Wei; Jingya Zhang; Ze Li; Honglei Feng; Li Ren
Journal:  Mol Med Rep       Date:  2020-07-28       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.